Post-neoadjuvant Treatment Efficacy Assessment in Breast Cancer
Conditions
Interventions
Patients with breast cancer receiving neoadjuvant therapy:None
Sponsors
Chongqing University Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients with breast cancer confirmed by biopsy pathology; 2.Aged 18–80 years old; 3.Planned to receive neoadjuvant therapy; 4.Lesions can be clearly measured on baseline ultrasound and MRI; 5.Patients fully informed and voluntarily signed the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Previous treatment history of ipsilateral breast cancer; 2.Pregnant or lactating women; 3.Combined with other severe malignant tumors or severe cardiac, hepatic and renal insufficiency, unable to tolerate neoadjuvant therapy or ultrasound contrast agents; 4.Allergy to sulfur hexafluoride ultrasound contrast agents; 5.Inability to cooperate with complete imaging examinations and follow-up;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological Complete Response (pCR);Ultrasound Imaging Biomarkers (e.g., contrast parameters, rate of elastography value change); | — |
Secondary
| Measure | Time frame |
|---|---|
| Predictive Model Performance Metric (AUC);Predictive Model Performance Metric (Recall/Sensitivity);Predictive Model Calibration; | — |
Countries
China
Contacts
Public ContactLi Fang
Chongqing University Cancer Hospital
Outcome results
None listed